What is Ado-trastuzumab emtansine?

Ado-trastuzumab emtansine, formerly known as trastuzumab-DM1 (T-DM1), is the first HER2 antibody-drug conjugate (ADC), consisting of Genentech's trastuzumab antibody linked to the immunogenic cell killer DM1. Trastuzumab combines two strategies, anti-HER2 activity and targeted intracellular delivery of the potent antimicrotubule agent DM1, a zeatin derivative, to produce cell cycle arrest and apoptosis.

Trastuzumab is marketed under the trade name Kadcyla and is indicated for patients with HER2-positive, metastatic cancer who have been treated with taxanes and/or trastuzumab for metastatic disease or whose cancer has recurred within 6 months of adjuvant therapy. Two caveats in the U.S. Food and Drug Administration's (FDA) prescribing guidelines include that trastuzumab and trastuzumab are not interchangeable, and a black box warning for serious side effects such as hepatotoxicity, embryo-fetotoxicity, and cardiotoxicity.

EnmetratrastuzumabThe monoclonal antigenic drug has been launched in China and has entered the scope of medical insurance. Only eligible patients can be reimbursed. SpecificationsThe price of 100mg per box may be around 20,000 yuan. This drug is a strictly controlled drug. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.